fashion -WSS

fashion

author：explore 2025-09-27 23:32:01 - browse：22

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Some top drug companies are starting to take action on climate

explore

WSS

6 solutions to address cancer drug shortages and others

Nobel honors Karikó and Weissman's enduring partnership

What we owe ALS patients — and why one company fell short

IVF doctors demand details after CooperSurgical lawsuit

RSV injection headlines need to be accurate for good uptake

Will an HIV vaccine ever be a reality?

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Continuity nursing helped my family in our darkest PICU moments

Florida health officials providing scant details on measles cases

Sports medicine is finally prioritizing gender equality

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Psychedelics group wrestles with new pharma identity

Longer MASH drug regimen improved liver, Akero study finds

Wildfire smoke exposes gaps in outdoor worker protections

Will an HIV vaccine ever be a reality?

hotspot

Lack of health data on LGBTQ+ people has serious consequences

The stability of $0 premiums in Medicare Advantage

New oral drug delivery patch is modeled after octopus tentacles

$1 billion proposal to grow Boston, Massachusetts biotech

What we owe ALS patients — and why one company fell short

IVG is promising — but it won’t replace IVF quite yet

explore

leisure time

explore

focus